FMS - Fresenius Medical Care AG & Co. KGaA

NYSE - NYSE Delayed Price. Currency in USD
40.08
+0.02 (+0.05%)
At close: 4:02PM EDT
Stock chart is not supported by your current browser
Previous Close40.06
Open39.85
Bid40.07 x 1000
Ask40.10 x 900
Day's Range39.76 - 40.13
52 Week Range30.99 - 53.40
Volume126,761
Avg. Volume214,819
Market Cap24.409B
Beta (3Y Monthly)1.94
PE Ratio (TTM)10.86
EPS (TTM)3.69
Earnings DateN/A
Forward Dividend & Yield0.63 (1.56%)
Ex-Dividend Date2018-05-21
1y Target Est43.97
Trade prices are not sourced from all markets
  • GlobeNewswire7 days ago

    SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Fresenius Medical Care AG & Co. KGaA  - FMS

    Pomerantz LLP is investigating claims on behalf of investors of Fresenius Medical Care AG & Co. KGaA (“Fresenius” or the “Company”) (NYSE: FMS).  Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext.

  • ACCESSWIRE9 days ago

    SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Fresenius Medical Care AG & Co. KGaA - FMS

    NEW YORK, NY / ACCESSWIRE / April 16, 2019 / Pomerantz LLP is investigating claims on behalf of investors of Fresenius Medical Care AG & Co. KGaA (''Fresenius'' or the ''Company'') (FMS). Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext. The investigation concerns whether Fresenius and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.

  • GlobeNewswire14 days ago

    SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Fresenius Medical Care AG & Co. KGaA - FMS

    Pomerantz LLP is investigating claims on behalf of investors of Fresenius Medical Care AG & Co. KGaA (“Fresenius” or the “Company”) (NYSE: FMS). Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext.

  • Fresenius Medical Care to pay $231M to resolve bribery charges
    American City Business Journals24 days ago

    Fresenius Medical Care to pay $231M to resolve bribery charges

    Fresenius Medical Care, a dialysis clinic operator, agreed Friday to pay $231 million in penalties to resolve allegations it paid bribes to win business deals in several countries, including Angola and Saudi Arabia.

  • Hedge Funds Have Never Been This Bullish On Fresenius Medical Care AG (FMS)?
    Insider Monkey27 days ago

    Hedge Funds Have Never Been This Bullish On Fresenius Medical Care AG (FMS)?

    Hedge fund managers like David Einhorn, Bill Ackman, or Carl Icahn became billionaires through reaping large profits for their investors, which is why piggybacking their stock picks may provide us with significant returns as well. Many hedge funds, like Paul Singer’s Elliott Management, are pretty secretive, but we can still get some insights by analyzing […]

  • Reuters28 days ago

    Fresenius Medical Care to pay $231 mln to resolve criminal, civil foreign bribery charges

    Germany-based dialysis clinic operator Fresenius Medical Care AG will pay about $231 million to resolve criminal and civil allegations that the company paid bribes to public health and government officials in several countries to win or retain business, the U.S. Justice Department said on Friday. The Justice Department agreed not to prosecute the company criminally in exchange for Fresenius paying a penalty of $84,715,273. The Securities and Exchange Commission, meanwhile, ordered the company to pay $147 million in disgorgement and prejudgment interest to settle the civil charges.

  • Reuters28 days ago

    Fresenius Medical Care says U.S. settlement will not affect 2019, 2020 results

    Fresenius Medical Care AG said that a $231.7 million U.S. settlement reached on Friday to resolve bribery allegations would have no impact on its 2019 and 2020 results because it had already made a financial ...

  • MarketWatch28 days ago

    Fresenius Medical Care to pay $231 million to settle bribery charges

    The Securities and Exchange Commission on Friday announced that Fresenius Medical Care AG & Co KGaA , a German medical device company, has agreed to pay over $231 million to settle charges brought by the Department of Justice and SEC. Fresenius was found to have violated the Foreign Corrupt Practices Act by falsifying documents as well as contracts and funneling bribes through third-party intermediaries. FMC paid nearly $30 million in bribes to government officials and others to procure business, the company said. "By engaging in widespread bribery schemes across multiple countries, the company prioritized profits over compliance in its dealings with foreign government officials," said Tracy Price, deputy chief of the SEC Enforcement Division's FCPA Unit, in a statement.

  • Fresenius Medical to Make Huge Investments, Competition Rife
    Zackslast month

    Fresenius Medical to Make Huge Investments, Competition Rife

    Fresenius Medical (FMS) is likely to make huge investments in India and China.

  • Fresenius Medical's New Hemodialysis Software Gets FDA Nod
    Zackslast month

    Fresenius Medical's New Hemodialysis Software Gets FDA Nod

    Fresenius Medical (FMS) offers a wide range of HD and PD dialysis products.

  • Baxter's (BAX) New Tie Up to Boost Acute Therapies Business
    Zackslast month

    Baxter's (BAX) New Tie Up to Boost Acute Therapies Business

    Baxter's (BAX) Acute Therapies business is expected to grow 7-8% in 2019.

  • The Wall Street Journallast month

    [$$] Fresenius Medical Care Readies for US Dialysis Shift

    , Secretary of the U.S. Department of Health and Human Services, said he wanted kidney-care to shift to a more value-based approach, favoring prevention and home care, and making transplants and artificial kidneys more accessible.

  • Should Value Investors Pick Fresenius Medical (FMS) Stock?
    Zackslast month

    Should Value Investors Pick Fresenius Medical (FMS) Stock?

    Let's see if Fresenius Medical (FMS) stock is a good choice for value-oriented investors right now, or if investors subscribing to this methodology should look elsewhere for top picks.

  • How Much Of Fresenius Medical Care AG & Co. KGaA (ETR:FME) Do Institutions Own?
    Simply Wall St.2 months ago

    How Much Of Fresenius Medical Care AG & Co. KGaA (ETR:FME) Do Institutions Own?

    If you want to know who really controls Fresenius Medical Care AG & Co. KGaA (ETR:FME), then you'll have to look at the makeup of its share registry. Large companiesRead More...

  • Reuters2 months ago

    U.S. seeks to cut dialysis costs with more home care versus clinics

    The goal is to reduce the $114 billion paid by the U.S. government each year to treat chronic kidney disease and end-stage renal disease, a top area of spending. The U.S. Centers for Medicare and Medicaid Services (CMS), which provides Medicare health benefits to more than 55 million Americans, is looking at a trial payment design that would improve care in the early stages of kidney disease, increase access to kidney transplants and favor home dialysis over clinic-based treatment, CMS head Seema Verma told Reuters in an interview.

  • Fresenius Medical (FMS) Earnings Beat, Revenues Miss in Q4
    Zacks2 months ago

    Fresenius Medical (FMS) Earnings Beat, Revenues Miss in Q4

    Fresenius Medical (FMS) sees higher Q4 revenues in EMEA and Asia Pacific regions.

  • PR Newswire2 months ago

    Fresenius Medical Care completes acquisition of NxStage Medical

    WALTHAM, Mass., Feb. 26, 2019 /PRNewswire/ -- Fresenius Medical Care, the world's largest provider of dialysis products and services, has successfully completed the acquisition of NxStage Medical, Inc. (NxStage), following approval by antitrust authorities in the United States. NxStage develops, produces and markets an innovative product portfolio of medical devices for use in home dialysis and critical care. The acquisition will enable Fresenius Medical Care to leverage its manufacturing, supply chain and marketing competencies across the dialysis products, services and Care Coordination businesses in a less labor- and capital-intensive care setting.

  • The Wall Street Journal2 months ago

    [$$] German Dialysis Firm Reaches Agreement in Bribery Probe

    German health-care firm Fresenius Medical Care AG said last week in a regulatory filing that it had reached an agreement in principle with U.S. authorities regarding a long-running foreign-bribery investigation that involved an anonymous whistleblower complaint. Fresenius said in the filing that it received communications beginning in 2012 that had alleged conduct outside the U.S. that might violate the Foreign Corrupt Practices Act or other antibribery laws. According to documents reviewed by The Wall Street Journal, an anonymous whistleblower sent an email in April 2012 to Fresenius managers and board members.

  • Reuters2 months ago

    FMC wraps up $2 bln acquisition of NxStage

    Germany's Fresenius Medical Care (FMC) wrapped up its $2 billion acquisition of U.S. home dialysis maker NxStage Medical on Friday, according to a U.S. Securities and Exchange Commission filing. The closure - some 18 months after FMC agreed to buy NxStage - paves the way for the world's biggest provider of dialysis services to scale up its home dialysis business by investing in new infrastructure, patient training and education.

  • Thomson Reuters StreetEvents2 months ago

    Edited Transcript of FME.DE earnings conference call or presentation 20-Feb-19 2:30pm GMT

    Q4 2018 Fresenius Medical Care AG & Co KGaA Earnings Call

  • ACCESSWIRE2 months ago

    Fresenius Medical Care AG & Co. KGaA: Fresenius Medical Care published form 20-F for the fiscal year 2018

    BAD HOMBURG, GERMANY / ACCESSWIRE / February 21, 2019 / Fresenius Medical Care, the world's largest provider of dialysis products and services, announced that it has filed the annual report 2018 under ...

  • Fresenius Medical Care AG & Co. (FMS) Q4 2018 Earnings Conference Call Transcript
    Motley Fool2 months ago

    Fresenius Medical Care AG & Co. (FMS) Q4 2018 Earnings Conference Call Transcript

    FMS earnings call for the period ending December 31, 2018.

  • FMC expects NxStage deal to close in next couple of days
    Reuters2 months ago

    FMC expects NxStage deal to close in next couple of days

    Germany's Fresenius Medical Care (FMC) said on Wednesday it has won the green light from U.S. regulators to acquire U.S. home dialysis equipment maker NxStage and expects the deal to close in the next few days. FMC agreed to buy NxStage in August 2017 for $2 billion but the deal has been held up due to competition concerns and most recently the U.S. government shutdown. "Very early this morning, we were notified the Federal Trade Commission has approved our NxStage deal," Chief Executive Rice Powell told reporters.

  • Reuters2 months ago

    Fresenius flags faster earnings growth from 2020 after investment

    Fresenius expects earnings to grow faster than sales from 2020 after investments to improve its German hospitals and scale up its home dialysis business eat up profit this year, the German healthcare group said on Wednesday. Investors, who were disappointed last year after the company trimmed its guidance in October and abandoned in 2020 targets in December, were heartened by the outlook and the prospect of a 7 percent increase in the dividend to 0.80 euros per share. "2019 will be a year of investment in growth areas such as home dialysis, biosimilars and new hospital services and therapies," Chief Executive Stefan Sturm said in a statement.